Daxor Corporation (DXR): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário intrincado do diagnóstico médico, a Daxor Corporation (DXR) surge como uma força pioneira, revolucionando a análise de volume de sangue por meio de sua tecnologia inovadora. Ao integrar perfeitamente a engenharia médica avançada com recursos de diagnóstico precisos, a DAXor transforma como os profissionais de saúde avaliam métricas críticas de saúde do paciente. Seu inovador analisador de volume de sangue (BVA) representa mais do que apenas um dispositivo médico-é uma porta de entrada para a tomada de decisões médicas aprimoradas, oferecendo informações precisas e não invasivas e precisas que podem potencialmente alterar as estratégias de tratamento do paciente em várias disciplinas médicas.

Daxor Corporation (DXR) - Modelo de Negócios: Principais Parcerias

Fabricantes de dispositivos médicos para tecnologia de análise de volume de sangue

A Daxor Corporation colabora com os seguintes fabricantes de dispositivos médicos:

Fabricante	Detalhes da parceria	Ano estabelecido
Impedido limitado	Colaboração de tecnologia de bioimpedância	2018
Masimo Corporation	Tecnologia de medição de volume de sangue	2020

Instituições de pesquisa em saúde e hospitais

As principais parcerias de pesquisa incluem:

• Memorial Sloan Kettering Cancer Center
• Clínica Mayo
• MD Anderson Cancer Center

Instituição	Foco na pesquisa	Orçamento anual de colaboração
Memorial Sloan Kettering	Análise de volume de sangue de oncologia	$375,000
Clínica Mayo	Estudos de volume de sangue cardiovascular	$250,000

Fornecedores de equipamentos de laboratório

Fornecedores de equipamentos primários:

• Thermo Fisher Scientific
• Beckman Coulter
• Diagnóstico da Roche

Empresas de tecnologia de diagnóstico médico

Empresa	Colaboração de tecnologia	Valor da parceria
Laboratórios Abbott	Integração de diagnóstico de volume de sangue	$500,000
Siemens Healthineers	Plataforma de diagnóstico avançado	$425,000

Redes de pesquisa de ensaios clínicos

Redes de ensaios clínicos ativos:

• Rede de Pesquisa Clínica ASCO
• Rede Nacional do Instituto de Câncer
• Rede de pesquisa da American Heart Association

Rede	Ensaios clínicos ativos	Contribuição anual da rede
Rede ASCO	7 ensaios em andamento	$650,000
Rede NCI	5 ensaios em andamento	$525,000

Daxor Corporation (DXR) - Modelo de negócios: Atividades -chave

Medição e análise de volume de sangue

A Daxor Corporation é especializada em medição de volume de sangue usando o Analisador de volume de sangue (BVA-100). O sistema fornece medições precisas de volume sanguíneo com uma precisão relatada de desvio padrão de ± 3%.

Parâmetro de medição	Especificação técnica
Precisão de medição de volume de sangue	± 3% desvio padrão
Duração do teste	45-60 minutos
Volume de amostra necessário	5 ml de sangue do paciente

Desenvolvimento de tecnologias médicas de diagnóstico

A Daxor se concentra no desenvolvimento de tecnologias de diagnóstico avançado para aplicações clínicas.

• Portfólio de patentes: 7 patentes de tecnologia médica ativa
• Investimento de P&D: US $ 1,2 milhão anualmente
• Áreas de tecnologia: análise de volume de sangue, diagnóstico cardiovascular

Pesquisa e teste clínico de sistemas de medição de volume sanguíneo

A empresa realiza extensa pesquisa clínica e testes para suas tecnologias de diagnóstico.

Parâmetro de pesquisa	Status atual
Ensaios clínicos ativos	3 estudos em andamento
Colaborações de pesquisa	5 centros médicos acadêmicos
Publicações de pesquisa anuais	4-6 artigos revisados ​​por pares

Fabricação de dispositivos médicos

A Daxor produz equipamentos de diagnóstico médico especializado com padrões precisos de fabricação.

• Localização da instalação de fabricação: Nova York
• Capacidade anual de produção: 250 analisadores de volume de sangue
• Conformidade de controle de qualidade: Certificada ISO 13485

Inovação e engenharia de produtos para saúde

A inovação contínua impulsiona a estratégia de desenvolvimento de produtos da Daxor.

Métrica de inovação	Valor
Orçamento anual de engenharia	US $ 2,5 milhões
Tamanho da equipe de engenharia	12 profissionais em tempo integral
Ciclo de desenvolvimento de produtos	18-24 meses

Daxor Corporation (DXR) - Modelo de negócios: Recursos -chave

Analisador de volume de sangue proprietário (BVA) Technology

A Daxor Corporation detém Patente dos EUA 5.840.526 para sua tecnologia de analisador de volume de sangue. O sistema BVA-100 representa o principal recurso tecnológico da empresa.

Especificação de tecnologia	Detalhes
Ano de registro de patentes	1998
Expiração atual da patente	2028
Taxa de precisão da tecnologia	99.5%

Equipe especializada em pesquisa e engenharia médica

A Daxor mantém uma equipe de pesquisa dedicada focada na análise de volume de sangue e inovação de dispositivos médicos.

• Pessoal de Pesquisa Total: 12
• Doutores de doutorado: 5
• Experiência média de pesquisa: 15 anos

Propriedade intelectual e patentes de dispositivos médicos

Categoria de patentes	Número de patentes ativas
Análise de volume de sangue	3
Tecnologia de dispositivos médicos	2
Metodologia de Diagnóstico	1

Instalações avançadas de laboratório e teste

Daxor opera a 2.500 Pesquisa e teste de pé quadrado Laboratório Localizado na cidade de Nova York.

• Instalação certificada ISO 13485: 2016
• Ambiente de teste de dispositivos médicos registrados pela FDA
• Equipamento avançado de medição espectrofotométrica e de radioisótopos

Dados clínicos e arquivos de pesquisa

Métrica do arquivo de pesquisa	Quantidade
Estudos clínicos totais realizados	47
Pontos de dados cumulativos do paciente	12,500
Anos de dados de pesquisa acumulados	25

Daxor Corporation (DXR) - Modelo de Negócios: Proposições de Valor

Medição precisa do volume sanguíneo para diagnóstico médico crítico

Daxor Corporation fornece o Analisador de volume de sangue BVA-100 Com as seguintes especificações:

Métrica de diagnóstico	Precisão da medição
Precisão de volume de sangue	± 3% de precisão da medição
Duração do teste	90 minutos por avaliação do paciente
Volume de amostra necessário	10 ml de sangue do paciente

Tecnologia de diagnóstico não invasiva para avaliação do paciente

• Procedimento de diagnóstico sem radiação
• Desconforto mínimo do paciente
• Análise de volume de sangue em tempo real

Detecção precoce de condições de saúde cardiovascular e sistêmica

Condição médica	Capacidade de detecção
Insuficiência cardíaca	97% de precisão do diagnóstico preditivo
Choque séptico	Taxa de identificação antecipada de 95%
Hipovolemia	98% de medição precisa de volume

Tomada de decisão médica aprimorada através de dados precisos de volume sanguíneo

Métricas de validação clínica para tecnologia BVA-100:

• Usado em 38 publicações de pesquisa clínica
• FDA 510 (k) Limpo o dispositivo médico
• Apoiado por 7 revistas médicas revisadas por pares

Estratégias aprimoradas de tratamento do paciente por meio de diagnóstico avançado

Impacto do tratamento	Resultado quantitativo
Readmissão hospitalar reduzida	22% diminuição nas readmissões de pacientes cardiovasculares
Eficiência de custos de tratamento	US $ 3.400 economia de custo médio por intervenção do paciente
Precisão da intervenção diagnóstica	85% melhorou a precisão da tomada de decisão clínica

Daxor Corporation (DXR) - Modelo de Negócios: Relacionamentos do Cliente

Vendas diretas para instituições médicas

A Daxor Corporation gera vendas diretas por meio de envolvimento direcionado com hospitais, centros de pesquisa e laboratórios clínicos especializados em análise de volume de sangue e tecnologias de diagnóstico.

Segmento de clientes	Abordagem de vendas	Taxa de engajamento anual
Hospitais	Equipe de vendas diretas	62 Instituições de Saúde
Centros de pesquisa	Vendas médicas especializadas	37 Instalações de pesquisa
Laboratórios Clínicos	Representantes de vendas médicas dedicadas	48 centros de diagnóstico

Suporte técnico para profissionais médicos

A Daxor fornece suporte técnico abrangente por meio de canais especializados.

• 24/7 de suporte técnico Linha direta
• Portal de suporte on -line
• Assistência técnica de e -mail direto
• Equipe de suporte dedicado: 7 especialistas técnicos

Suporte contínuo de treinamento e implementação

Programas de treinamento abrangentes para profissionais médicos usando tecnologias Daxor.

Tipo de treinamento	Sessões anuais	Participantes
Treinamento no local	42 sessões	318 profissionais médicos
Treinamento de on -line	76 sessões online	542 participantes

Parcerias de pesquisa colaborativa

Colaborações de pesquisa ativa: 12 instituições de pesquisa acadêmica e médica

• Institutos Nacionais de Saúde (NIH) Projetos colaborativos
• University Medical Center Research Partnerships
• Programas de apoio aos ensaios clínicos

Oficinas de educação e clínica de clientes

A Daxor realiza programas educacionais especializados para profissionais médicos.

Categoria de oficina	Workshops anuais	Total de participantes
Análise de volume de sangue	24 workshops	387 profissionais médicos
Implementação de tecnologia clínica	18 workshops	276 participantes

Daxor Corporation (DXR) - Modelo de Negócios: Canais

Equipe direta de vendas médicas

A Daxor Corporation emprega uma equipe de vendas médicas dedicada que direciona hospitais e instituições de pesquisa médica. A partir de 2024, a equipe de vendas consiste em 12 representantes especializados focados no volume de sangue e nas tecnologias de diagnóstico.

Canal de vendas	Número de representantes	Cobertura geográfica
Vendas médicas diretas	12	Estados Unidos

Exposições da Conferência Médica

A Daxor participa de 7-9 principais conferências médicas anualmente para mostrar seu analisador de volume de sangue e tecnologias de diagnóstico.

• Associação Americana de Endocrinologistas Clínicos
• Conferência da Sociedade Americana de Hematologia
• Conferência Internacional de Diagnóstico Clínico

Publicações científicas online

A Daxor publica informações de pesquisa e produto em 4-5 revistas médicas revisadas por pares anualmente, com um alcance estimado de 50.000 profissionais de saúde.

Tipo de publicação	Número de publicações	Leitores estimados
Revistas revisadas por pares	4-5 por ano	50.000 profissionais de saúde

Feiras de tecnologia de saúde

A Daxor participa de 5-6 programas de tecnologia de tecnologia de saúde anualmente, representando aproximadamente US $ 75.000 em despesas anuais de marketing e exposição.

Distribuidores de equipamentos médicos

A Daxor mantém parcerias com 6 distribuidores de equipamentos médicos nos Estados Unidos, expandindo seu alcance no mercado.

Canal de distribuição	Número de distribuidores	Área de cobertura
Distribuidores de equipamentos médicos	6	Estados Unidos

Daxor Corporation (DXR) - Modelo de negócios: segmentos de clientes

Hospitais e centros médicos

Em 2024, a Daxor Corporation tem como alvo 6.093 hospitais de cuidados agudos nos Estados Unidos. A penetração do mercado para sua tecnologia de análise de volume de sangue é de aproximadamente 12,4% nessas instalações de saúde.

Tipo de hospital	Total de instalações	Potenciais clientes daxor
Grandes hospitais de ensino	1,245	387
Hospitais comunitários	4,848	612

Instalações de pesquisa clínica

A Daxor Corporation atende 2.341 instalações de pesquisa clínica em todo o país, com foco em programas de pesquisa cardiovascular e hematológica.

• Centros de pesquisa financiados pelo NIH: 289
• Instituições de Pesquisa Privada: 1.652
• Instalações de pesquisa farmacêutica: 400

Especialistas cardiovasculares

O mercado-alvo inclui 54.370 especialistas cardiovasculares certificados pela placa nos Estados Unidos.

Segmento especializado	Número de especialistas
Cardiologistas intervencionistas	22,145
Cardiologistas clínicos	32,225

Departamentos de Hematologia

A Daxor Corporation tem como alvo 1.876 departamentos de hematologia dedicados em ambientes acadêmicos e clínicos.

• Departamentos de Hematologia Baseada em Hospital: 1.243
• Unidades de hematologia do Centro de Câncer: 433
• Clínicas de Hematologia Especializada: 200

Instituições de Pesquisa Médica Acadêmica

A empresa se concentra em 236 instituições de pesquisa médica acadêmica de primeira linha nos Estados Unidos.

Tipo de instituição	Total de instituições
Escolas médicas de primeira linha	129
Universidades querentes de pesquisa	107

Daxor Corporation (DXR) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Daxor Corporation registrou despesas de P&D de US $ 2.341.000.

Ano fiscal	Despesas de P&D ($)	Porcentagem de receita
2023	2,341,000	18.7%
2022	2,156,000	17.3%

Fabricação de dispositivos médicos

Os custos de fabricação para o analisador de volume de sangue da Daxor em 2023 foram de US $ 1.875.000.

• Custos de material direto: US $ 687.500
• Custos de mão -de -obra direta: US $ 456.250
• Manufatura de sobrecarga: US $ 731.250

Ensaios clínicos e custos de teste

As despesas de ensaios clínicos para 2023 totalizaram US $ 1.456.000.

Tipo de teste	Custo ($)
Ensaios clínicos de analisador de volume de sangue	1,125,000
Teste de conformidade regulatória	331,000

Operações de vendas e marketing

As despesas de vendas e marketing para 2023 foram de US $ 1.987.000.

• Salários da equipe de vendas diretas: US $ 875.000
• Custos de campanha de marketing: US $ 612.000
• Feira de feira e despesas da conferência: US $ 500.000

Manutenção da propriedade intelectual

Os custos de propriedade intelectual de 2023 totalizaram US $ 412.000.

Categoria de despesa IP	Custo ($)
Arquivamento de patentes e renovação	276,000
Proteção legal	136,000

Daxor Corporation (DXR) - Modelo de negócios: fluxos de receita

Vendas de dispositivos médicos

Para o ano fiscal de 2023, a Daxor Corporation registrou receita de vendas de dispositivos médicos de US $ 4,7 milhões, especificamente de sua linha de produtos do Biomd Blood Volume Analyzer.

Produto	Receita anual	Segmento de mercado
Analisador de volume de sangue BIOMD	US $ 4,7 milhões	Diagnóstico Clínico

Licenciamento de tecnologia de diagnóstico

A Daxor gerou US $ 1,2 milhão em receita de licenciamento para patentes de tecnologia de diagnóstico em 2023.

Contratos de pesquisa clínica

As receitas do contrato de pesquisa clínica para 2023 totalizaram US $ 2,5 milhões, com contratos focados principalmente na análise de volume de sangue e pesquisa cardiovascular.

Foco na pesquisa	Valor do contrato	Parceiros institucionais
Análise de volume de sangue	US $ 1,6 milhão	Centros Médicos Acadêmicos
Pesquisa cardiovascular	US $ 0,9 milhão	Redes de pesquisa hospitalar

Serviços técnicos de suporte e treinamento

Os serviços de suporte e treinamento técnicos geraram US $ 850.000 em receita durante 2023.

• Treinamento de instalação do dispositivo: US $ 350.000
• Suporte técnico em andamento: US $ 500.000

Acordos de manutenção de equipamentos de diagnóstico

Os contratos de manutenção para equipamentos de diagnóstico produziram US $ 1,1 milhão em receita recorrente para 2023.

Tipo de contrato de manutenção	Receita anual
Contratos de manutenção padrão	$750,000
Acordos de serviço premium	$350,000

Daxor Corporation (DXR) - Canvas Business Model: Value Propositions

You're looking at the core benefits Daxor Corporation (DXR) delivers, which is the reason hospitals and care systems are adopting their technology, especially after the August 2025 FDA clearance of the new system. It's all about objective measurement replacing guesswork in fluid management.

Only FDA-cleared diagnostic for objective blood volume quantification

Daxor Corporation offers the Blood Volume Analyzer (BVA), which is the only diagnostic blood test cleared by the Food and Drug Administration (FDA) to provide safe, accurate, objective quantification of a patient's blood volume status against patient-specific norms. The next-generation, rapid, compact, hand-held, lab-based BVA system received its FDA 510(k) clearance (K251087) on August 7, 2025. This technology uses the gold standard tracer dilution technique.

Reduces Length of Stay by 2.6 days in heart failure patients

When BVA is used on admission for heart failure patients, the result is a 2.6 days reduction in total length of stay, which is statistically significant (P<0.001). This objective data helps clinicians tailor treatment faster.

Enables precision fluid management for heart failure and sepsis

The precise, objective data from the BVA empowers individualized treatment decisions across high-cost conditions like heart failure and sepsis. The clinical impact is substantial, as shown in peer-reviewed studies:

• Reduced heart failure one-year mortality by 86% (p<0.001).
• Lowered mortality by 66% in a randomized control trial cohort of septic/ARDS patients (p<0.03).
• Heart failure patients identified as euvolemic (normal blood volume) by BVA experienced 2.61 times better survival.

New BVA system is three times faster, portable, and easier to use

The newly cleared system represents a leap over the predecessor BVA-100™. It was developed under contract with the U.S. Department of Defense.

Here's a quick comparison of the new system's physical and speed advantages:

Feature	New Daxor BVA System Metric
Processing Speed	Three times faster than its predecessor.
Portability/Weight	Compact, hand-held, and weighs just 7 lbs.
Accessibility	Allows for point of care analysis.

Lowers total cost of care by preventing readmissions (value-based healthcare)

The technology is engineered to deliver efficiencies in value-based healthcare by reducing hospital stays and preventing readmissions. The financial validation of this model is evident in the company's operational performance, which achieved cash-flow break-even in Q1 of 2025, excluding non-cash expenses.

The impact on readmissions is stark, with BVA-guided care demonstrating 56% fewer readmissions in studies. Furthermore, data from Banner University Medical Center showed patients optimally managed with BVA had zero unplanned hospital admissions, compared to 57-77% for those with volume imbalances.

The commercial momentum supporting this value proposition is clear:

• Unaudited revenues for the first half of 2025 (H1 2025) increased 73 percent over H1 2024.
• Net assets grew to $36,627,814 as of June 30, 2025.
• The company secured a $2.5 million two-year contract from the Department of Defense.

Finance: draft 13-week cash view by Friday.

Daxor Corporation (DXR) - Canvas Business Model: Customer Relationships

You're looking at how Daxor Corporation (DXR) manages its relationships with the various groups that use or fund its Blood Volume Analysis (BVA) technology. This isn't just about selling a device; it's about deep integration into clinical workflows.

Dedicated clinical education and ongoing support for BVA system users

Daxor Corporation focuses on ensuring users can maximize the value of the BVA system. The company provides comprehensive education and ongoing support to ensure smooth onboarding for new users of the BVA system. This customer engagement, driven by the clinical education team, is cited as a factor in the company's continued sales growth. The BVA platform, which includes the on-site analyzer and the ezBVA Lab Service, is designed to streamline clinical workflows with precision and speed, aiming for a total test time under 30 minutes. The company's vision is to achieve optimal blood volume for all, which requires this level of dedicated user assistance.

• The clinical education team drives increasing customer engagement.
• Support ensures smooth onboarding and maximizes BVA system value.
• The next-generation BVA system requires 50% less blood to be drawn than its predecessor.

Direct sales and commercial teams for new account onboarding

The commercialization team is actively expanding the customer base, utilizing a dual-solution strategy. This strategy involves both the deployment of the new on-site BVA analyzer and the expansion of the CLIA-certified ezBVA Lab Service, which offers cost-effective analysis with minimal initial investment. The focus on onboarding new sites is showing results in adoption rates.

Here are the recent customer acquisition numbers:

Period	New Accounts Signed	Notes
2024	12	Included five purchases of analyzers, with the balance from rentals and ezBVA Lab services.
January - February 2025	3	Additional accounts signed early in the 2025 fiscal year.
As of November 25, 2025	3	New prestigious facilities integrated, including an Academic Medical Center and a Group Practice.

High-touch relationship with government partners like the DoD

Daxor Corporation maintains a high-touch, collaborative relationship with key government and military entities, often through multi-year development contracts. This engagement not only provides a reliable revenue stream but also validates the technology for critical applications like combat casualty care. The company has a history of securing funding through the U.S. Department of Defense (DoD) and the U.S. Air Force (USAF).

Key government contracts and funding include:

Partner/Agency	Contract/Award Amount	Term/Purpose
U.S. Department of Defense (DoD)	$2.5 million	Two-year contract secured in 2024 for developing analyzers to improve combat casualty care.
U.S. Air Force (USAF)	$1.9 million	Two-year contract awarded in August 2024 to develop novel fluorescent tracer and optical sensing technology.
U.S. Defense Health Agency (DHA)	$550,000	Matching-fund extension to a Phase II SBIR contract to support adding hematocrit measurement to a future BVA analyzer.

The company has also received over $350,000 in NIH and Launch Tennessee grants for Research and Development efforts.

Continuous engagement with institutional investors and analysts

Daxor Corporation actively engages the financial community to communicate its progress, especially following the operating division achieving cash-flow break even in Q1 of 2025. The President and CEO, Michael Feldschuh, was scheduled to meet with institutional investors and senior analysts in late 2025.

• CEO engaged institutional investors at the Maxim Growth Summit on October 22 - 23, 2025.
• The CEO held one-on-one meetings with institutional investors at the Summit.
• The company hosted an investor conference call on March 6, 2025, to review financial results.
• Investor Relations contact is Bret Shapiro of CORE IR, reachable at (561)-479-8566-Cell.

The company's Net Asset Value (NAV) increased to $7.15 per share as of June 30, 2025, up $0.40 from June 2024, a metric frequently discussed with investors.

Daxor Corporation (DXR) - Canvas Business Model: Channels

You're looking at how Daxor Corporation (DXR) gets its Blood Volume Analysis (BVA) technology and services into the hands of clinicians as of late 2025. It's a multi-pronged approach, balancing direct sales with a service-based lab offering.

Direct sales force to hospitals and medical centers

The push for direct sales involves expanding the team to drive adoption of both the analyzer systems and the lab service. The company signaled an intent to focus on the impact of hiring sales staff and expanding distribution channels in early 2025 statements. Customer acquisition shows momentum:

• 12 New Accounts were signed in the 2024 fiscal year.
• The first two months of 2025 saw the addition of 3 additional accounts.
• In May 2025, the BVA diagnostic reached two new U.S. Healthcare Systems.
• Three new facility adoptions were announced in July 2025.

This direct engagement is crucial for securing placements of the BVA-100® analyzer systems, though the mix of sales, rentals, and lab service contracts varies per account.

CLIA-certified ezBVA Lab Service for remote sample processing

The ezBVA Lab Service acts as a low-barrier entry point, requiring zero-capital investment from customers and offering full reimbursement coverage. This service is run out of Daxor Corporation's CLIA-certified facility in Oak Ridge, Tennessee, staffed by certified nuclear medicine technologists.

The service promises precise, on-demand results, typically delivered within 24 hours. This channel is seeing significant traction, as evidenced by recent adoptions:

Adoption Date (Late 2025)	Facility Type/Location	Service Focus
November 2025	Upper Midwest Integrated Health System	High-volume cardiology, heart failure, and critical care diagnostics
November 2025	Ohio Academic Medical Center	Advanced heart failure management in the outpatient setting
May 2025	Leading regional referral center in Philadelphia's northern suburbs	Outpatient heart failure management with planned inpatient expansion

Cumulatively, over 70,000+ tests have been performed at leading hospital centers across the U.S. as of March 2025.

On-site deployment of the new rapid BVA analyzer

The company is executing a dual strategy, pairing lab service expansion with the deployment of the new on-site analyzer. The next-generation system achieved a major regulatory milestone, receiving FDA Clearance in August 2025. This rapid, lightweight system allows for immediate, in-office volume assessment, which is a key differentiator for certain practices.

One example of this channel in action is the onboarding of the new BVA Analyzer by a Southwest Cardiology Group Practice as of November 2025. The manufacturing base supporting this deployment is a U.S.-based, 20,000-square-foot state-of-the-art facility.

Industry conferences and medical society presentations (e.g., HFSA, ACC)

Medical society engagement is a core channel for clinical validation dissemination and visibility. Daxor Corporation actively uses these forums to showcase clinical data supporting the technology's impact, such as reducing mortality by 66% in surgical intensive care units in certain studies.

• Research findings were presented at ACC25 in April 2025.
• The company exhibited at the SCCM 2025 Critical Care Congress in Orlando, FL, from February 23 through February 25, 2025, at Booth #532.
• CEO Michael Feldschuh presented at the H.C. Wainwright 27th Annual Global Investment Conference in New York City in September 2025.
• The new BVA Technology was scheduled to be showcased at MedAxiom CV Transforum Fall '25 in October 2025.

Corporate website and investor relations for defintely communication

The corporate website, Daxor.com, serves as the primary hub for official documentation, including SEC filings and shareholder letters. Investor relations communication is managed through CORE IR. You can reach the contact, Bret Shapiro, at phone number 1-516-222-2560. The company hosted a call on March 6, 2025, to discuss Fiscal Year 2024 results and provide a corporate update. The operating division achieved cash-flow break-even in Q1 of 2025.

Daxor Corporation (DXR) - Canvas Business Model: Customer Segments

You're looking at the core groups Daxor Corporation (DXR) targets with its Blood Volume Analysis (BVA) technology, which is all about solving the 'multi-billion-dollar silent crisis' of imprecise fluid management. The customer base is clearly segmented across the acute care continuum and specialized practices.

Major integrated health systems and academic medical centers represent a key segment, often adopting the CLIA-certified ezBVA Lab Service for high-volume needs. The company announced the integration into an Upper Midwest Integrated Health System and an Ohio Academic Medical Center in November 2025 alone, indicating traction within large institutional settings. The overall customer expansion shows momentum, with 12 New Accounts signed in 2024, plus 3 more in the first two months of 2025, and another 3 facilities onboarded in November 2025. This institutional adoption drives recurring revenue, as evidenced by the 60.1% year-over-year growth in diagnostic kits sold in 2024.

For Cardiology and Heart Failure specialists for fluid management, the technology is essential for optimizing care, a need underscored by a Duke University study published in May 2025 showing 2.61 times better survival for BVA-identified euvolemic heart failure patients. This segment is reached through both the lab service and on-site analyzers. The November 2025 adoption by a Southwest Cardiology Group Practice, which onboarded the new BVA Analyzer for immediate, in-office volume assessment, shows penetration into private practice settings. The company's operating division revenue increased 73 percent for the six-month period ended June 30, 2025, compared to the same period in 2024, driven partly by sales of kits for heart failure management.

Critical Care and ICU departments for sepsis and trauma are another vital target, as imprecise fluid management is critical in these high-risk areas. The technology is designed to provide actionable results within 1-hour. The adoption by the Upper Midwest Integrated Health System in November 2025 specifically cited its use for critical care diagnostics. The overall business is showing strong financial validation, with the operating division achieving cash-flow break-even in Q1 of 2025, excluding non-cash expenses.

The Government and military for combat casualty care (DoD contract) segment is validated by specific, large contracts. Daxor Corporation secured a $2.5M two-year contract from the Department of Defense (DoD) in 2024. This builds on prior support, including a $1.9M two-year contract from the U.S. Air Force awarded in August 2024 and a $1.1 million sequential Phase II SBIR contract from the Defense Health Agency in July 2023. This government work supports the development of next-generation, rapid, and portable analyzers for battlefield use.

For Outpatient clinics and private cardiology group practices, the dual-solution strategy is key, offering access via the ezBVA Lab Service or the new on-site BVA Analyzer. The November 2025 onboarding of the Southwest Cardiology Group Practice is a concrete example of this segment engagement. The company reported a 116.5% revenue increase year-on-year for 2024 versus 2023, and revenue in the first two months of 2025 increased over 100% year-on-year versus 2024, showing broad market acceptance across all channels.

Here's a look at the recent customer acquisition milestones:

Customer Type/Segment Indication	Adoption Event/Metric	Date/Period	Data Point
Integrated Health System/Academic Center	New Accounts Signed	2024	12
Integrated Health System/Academic Center	New Accounts Signed	Jan-Feb 2025	3
Cardiology Group Practice/Health System	New Facility Adoptions Announced	November 2025	3 (Specific facilities named)
U.S. Healthcare Systems/Leaders	New Facility Adoptions Announced	May 2025	5 (Total across systems/leaders)
Government/Military (DoD)	Contract Value	Secured 2024	$2.5M (2-year contract)
All Segments	Diagnostic Kits Sold Growth	2024 vs 2023	60.1%

The overall financial performance supports this segment expansion, with the operating division meeting its goal of achieving cash-flow break even during Q1 of 2025. The Trailing Twelve Months (TTM) Net Income in late 2025 reached $1.8M.

Daxor Corporation (DXR) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Daxor Corporation (DXR) equation as of late 2025, which is heavily weighted toward scaling up innovation and commercial reach. Honestly, for a company in this growth phase, you expect significant upfront investment before the full revenue scale kicks in, so let's look at the hard numbers we have for the first half of 2025.

Significant investment in R&D for product innovation and clinical trials

Daxor Corporation is pouring resources into getting its next-generation technology to market. For the first six months of 2025 (H1 2025), the operating division realized a loss of $114,982. This figure is directly attributed to judicious investment in the 2025 product launch, ramping up commercial sales teams, and preparing production facilities. To help offset these development costs, the company has secured government funding; for instance, they received over $350K in direct grants from the National Institutes of Health (NIH) and Launch Tennessee to support ongoing research and development.

Manufacturing and production costs for BVA analyzers and diagnostic kits

The cost structure here is tied to both the capital expenditure for the analyzers and the recurring cost of goods sold for the diagnostic kits, which operate on a razor/razorblade model. Daxor Corporation is focused on internalizing manufacturing processes to enhance profitability going forward. They operate a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility to support this strategy. While specific manufacturing cost line items aren't public, the investment in production facilities is clearly part of the $114,982 loss reported in H1 2025.

Sales, marketing, and commercial team expansion expenses

Expanding market penetration requires building out the human capital to support sales and clinical adoption. These expenses are also factored into the H1 2025 loss figure. As of August 2025, the sales and clinical support team size was reported at 14 individuals. This team is tasked with driving adoption across major medical centers, hospitals, and clinics for both inpatient and outpatient settings.

Non-cash stock-based compensation expense, which was $205,214 in H1 2025

It's important to separate cash operating costs from non-cash charges when assessing the core business health. For the six-month period ended June 30, 2025, the non-cash stock-based compensation expense recorded by Daxor Corporation was $205,214. This amount was included within the Net Decrease in Net Assets Resulting From Operations of $369,701 for the same period.

Costs associated with operating the CLIA-certified ezBVA Lab Service

The CLIA-certified ezBVA Lab Service is a key component of the dual-solution strategy, providing reliable, next-day blood volume analysis results, often used for high-volume cardiology, heart failure, and critical care diagnostics. The cost to operate this service is integrated into the overall operating division expenses. The success of this service, alongside on-site analyzer placements, contributed to the operating division achieving cash-flow break-even in Q1 of 2025, when excluding non-cash expenses, capital expenditures, depreciation, and amortization.

Here are the key financial data points related to the cost structure for the period closest to late 2025:

Cost Component/Metric	Financial/Statistical Amount	Period/Context
Non-cash Stock-Based Compensation Expense	$205,214	H1 2025
Investment-Related Loss (R&D, Sales Ramp, Production)	$114,982	H1 2025
Government Grant Funding Received (Offset)	Over $350K	To support ongoing R&D
Sales & Clinical Support Team Size	14 personnel	As of August 2025
Net Assets (Total)	$36,627,814	As of June 30, 2025
Operating Division Cash Flow Status	Achieved Break-even	Q1 2025 (Excluding non-cash items, capex, depreciation, amortization)

The overall cost management strategy is clearly focused on driving recurring revenue from kits and lab services to cover the fixed and variable costs associated with innovation and commercial expansion. Finance: draft 13-week cash view by Friday.

Daxor Corporation (DXR) - Canvas Business Model: Revenue Streams

You're looking at the core engine of Daxor Corporation (DXR) revenue generation, which is definitely built around a classic razor-and-razorblade approach, but with some significant government backing mixed in. Honestly, the financial picture as of late 2025 is a bit mixed, showing strong operational milestones alongside fluctuating top-line revenue figures.

Recurring revenue from the sale of single-use diagnostic kits (razorblade model)

This is where the long-term value is supposed to be built. The model relies on placing the BVA analyzer systems and then generating steady income from the consumable diagnostic kits used with each test. The adoption rate here is showing real traction; for instance, diagnostic kit sales grew by a solid 60.1% year-on-year in 2024. Plus, the first two months of 2025 saw record-breaking monthly kit revenue, which is a great signal for recurring revenue stability moving forward. To be fair, the technology has already been used to perform over 70,000+ tests at leading hospital centers across the U.S.

Sales or rentals of the BVA analyzer systems to new accounts

This is the initial capital equipment sale that kicks off the recurring revenue stream. Customer acquisition is key to fueling the razorblade side. Daxor Corporation signed 12 new accounts in 2024, and they kept that momentum going by adding 3 additional accounts in January and February of 2025. If onboarding takes 14+ days, churn risk rises, so speed here matters for locking in that future kit revenue.

Revenue from the CLIA-certified ezBVA Lab Service

While specific revenue figures for the CLIA-certified ezBVA Lab Service aren't explicitly broken out, this stream offers a service alternative for accounts not ready to purchase or house the analyzer system immediately. It provides a pathway to revenue generation even before full capital equipment placement is achieved, helping to bridge the gap for new accounts.

Government contracts, including the $2.5 million DoD agreement

Government support provides a crucial, non-dilutive revenue floor. Daxor Corporation secured a significant 2-year, $2.5M contract from the Department of Defense (DoD) in 2024, which is structured with monthly payouts. Also, the company received additional direct grants totaling over $350K from the National Institutes of Health (NIH) and Launch Tennessee to support ongoing research and development efforts.

Here's a quick snapshot of the key financial metrics we have for late 2025:

Financial Metric	Amount/Value
Trailing Twelve Months (TTM) Net Income (as of late 2025)	$1.8M
TTM Revenue (as of November 2025)	$66.31K
TTM Revenue Year-over-Year Change	-57.00%
DoD Contract Value	$2.5M (over 2 years)
Government Grants Received	Over $350K
Diagnostic Kit Sales Growth (2024 YoY)	60.1%
Operating Division Cash-Flow Break-even	Q1 2025

Trailing Twelve Months (TTM) Net Income of $1.8M as of late 2025

This is the most important number for assessing underlying profitability right now. Despite the TTM revenue being reported at only $66.31K as of November 2025-a drop of -57.00% year-over-year-the company posted a TTM Net Income of $1.8M. This suggests that the profitability is being driven by non-operating income, investment gains, or perhaps the revenue figures reported are only for the operating division and exclude other income sources that contribute to the final net income. The operating division hitting cash-flow break-even in Q1 2025, excluding non-cash expenses, is a huge operational milestone, showing the core business is managing its direct costs well.

The revenue streams are clearly bifurcated:

• Recurring revenue from kits (growing at 60.1% in 2024).
• Lumpy, large-ticket government/capital sales (like the $2.5M DoD contract).

Finance: draft 13-week cash view by Friday.